title: [High-dosage chemotherapy with support of autologous haematopoietic cells in the treatment of multiple myeloma--review of contemporary possibilities].
abstract: High-dosage chemotherapy with autologous transplantation of haematopietic stem cells prolonged the survival of patients with multiple myeloma as compared with results of standard chemotherapy, on average by 1.5 years. Nowadays this method is the standard treatment for suitable patients. Findings assembled recently are discussed by the authors.
authors.affiliation: Interni hematoonkologická klinika FN Brno.
authors.forename: Z
authors.initials: Z
authors.lastname: Rácil
authors.forename: Z
authors.initials: Z
authors.lastname: Adam
authors.forename: R
authors.initials: R
authors.lastname: Hájek
authors.forename: M
authors.initials: M
authors.lastname: Tomíska
authors.forename: M
authors.initials: M
authors.lastname: Krejcí
authors.forename: A
authors.initials: A
authors.lastname: Krivanová
authors.forename: J
authors.initials: J
authors.lastname: Höklová
authors.forename: M
authors.initials: M
authors.lastname: Doubek
authors.forename: J
authors.initials: J
authors.lastname: Mayer
authors.forename: J
authors.initials: J
authors.lastname: Vorlícek
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009101:Multiple Myeloma / Q000628:therapy*; D014182:Transplantation, Autologous
chemical_list: D000970:Antineoplastic Agents